FF 21101-Y-90 Phase I

Katrina’ reported the following:

I began this second part of a Phase I study on this radiotherapy (immunology) y90 plus antibody at MD Anderson. It is for any solid tumors I believe. MY first CT last week showed my 3 little tumors to be “Stable.” Stable works for me. The Trial, under Dr. Subbyia(?) began last January. The team has told me that it is doing well all round with all the types of cancer trial patients they have tried. Good news: No side effects!!! Wow. Bad news: The first 5 months, you may have to visit MDa WEEKLY even if only for blood tests. If you need at least stable, this is an option as long as they have slots.
Katrina

A Phase 1 clinical trial of FUJIFILM’s radioimmunotherapeutic agent FF-21101 in the United States in patients with advanced solid tumor cancers. The trial is being performed at The University of Texas MD Anderson Cancer Center with Vivek Subbiah, M.D., as the Principal Investigator. Dr. Subbiah is an Assistant Professor in the Department of Investigational Therapeutics and an expert in Phase 1 cancer clinical research of molecularly-targeted radiopharmaceuticals.